Skip to content

ClearPoint Neuro CLPT Long-Term Debt

Long-Term Debt at other companies

Abbott logo
AbbottABT
$29.64B+133%
IAR
Integra LifeSciencesIART
$1.75B+55.1%
Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
$6.3B-4.3%
Medtronic logo
MedtronicMDT
$26.17B+2.1%
Orthofix Medical Inc. logo
Orthofix Medical Inc.OFIX
$221.34M+41.1%
Neuropace, Inc. logo
Neuropace, Inc.NPCE
$59.02M-1.3%

Other financials

Income statement

See full
Revenue$12.1M+42.9%
Gross profit$7.8M+51.1%
Operating income-$8.5M-37.6%
Net income-$9.6M-58.5%
EPS (diluted)-$0.32-45.5%

Balance sheet

See full
Cash & equivalents$36.5M+195%
Total debt$63.6M+1,750%
Total equity$18.8M-5.7%
Total assets$93.4M+211%

Cash flow

See full
Operating cash flow-$8.0M-29.1%
CapEx$645.0K+252%
Free cash flow-$8.6M-35.5%

Valuation

See full
Market cap$538.61M+69.2%
Enterprise value$565.68M+82.9%
P/S13.3×+3.4×

Profitability

See full
Gross margin62.3%+1.1pp
Operating margin-65.2%-1.9pp
Net margin-71.6%+8.8pp
FCF margin-65.7%+269pp

Returns & leverage

See full
Return on equity-149.7%+4,074pp
Debt / equity3.4×+3.2×
Current ratio5.8×+2.3×

Where this comes from

Reported directly by ClearPoint Neuro in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebt.

The official record: ClearPoint Neuro’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about ClearPoint Neuro's long-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ClearPoint Neuro's long-term debt?
ClearPoint Neuro (CLPT) reported long-term debt of $49.64M in Q1 2026.
What is the long-term trend for ClearPoint Neuro's long-term debt?
Over 5 years (2020 to 2025), ClearPoint Neuro's long-term debt has grown at a 18.2% compound annual growth rate (CAGR), from $21.28M to $49.08M.
What does long-term debt mean?
Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.